Skip to main content

Advertisement

Table 2 Characteristics of treatment regimens of the 30 rifampicin monoresistant tuberculosis patients included in the outcome analysis by outcome and for those with extrapulmonary tuberculosis

From: Rifampicin mono-resistant tuberculosis in France: a 2005–2010 retrospective cohort analysis

Treatment characteristic Total patients (n = 30) Outcome Extrapulmonary tuberculosis° n = 10
Recovery (n = 20) Lost to follow-up (n = 4) Dead (n = 3) Relapse (n = 3)
Total duration of treatment       
 < 6 months 4 (13%)   1 21 11 2
 6 to <9 months 2 (7%) 1   11   0
 9–12 months 13 (44%) 92 2   21 7
 13–24 months 11 (37%) 102 1    1
Total FQuinolones (no AG) 13 (43%) 7 (35%) 1 (25%) 3(100%) 2 (66%) 6 (60%)
 1–3 months 3   1 32   2
 4–6 months 1      0
 > 6 months 9 7    21 4
Total AG (no FQuinolone) 4 (13%) 3 (15%) 1 (25%) 0 0 1 (10%)
 1–3 months 3 2 1    1
 > 3 months 1 1     0
FQuinolones and AG* 8 (26%) 6 (30%) 1 (25%) 0 1 (33%) 1 (10%)
Duration of AG       
 1–3 months 6 53    11 0
 > 3 months 2 1 1    1
Duration of FQuinolones       
 1–3 months 2 21     1
 4–6 months 1   1    0
 > 6 months 5 41    11 0
  1. Numbers in indices indicate the number of HIV co-infected patients for the category, if any.
  2. FQuinolones = any fluoroquinolone, AG = any aminoglycoside.
  3. *Duration of the combination of at least one month.
  4. °: 5 pulmonary and extrapulmonary tuberculosis and 5 with only extrapulmonary tuberculosis.